Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM)’s share price dropped NaN during trading on Friday . The company traded as low as $8.25 and last traded at $0.00. Approximately 760,842 shares traded hands during trading, an increase of Infinity from the average daily volume of 0 shares.

MTEM has been the subject of a number of analyst reports. ValuEngine downgraded Threshold Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, June 29th. Stifel Nicolaus reissued a “hold” rating and set a $0.40 price objective on shares of Threshold Pharmaceuticals in a research report on Thursday, August 3rd. Ladenburg Thalmann Financial Services assumed coverage on Threshold Pharmaceuticals in a report on Thursday, August 3rd. They issued a “buy” rating and a $10.00 price target for the company. Finally, Zacks Investment Research downgraded Threshold Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, September 14th.

The stock’s 50-day moving average price is $5.63 and its 200 day moving average price is $5.59. The firm’s market capitalization is $244.89 million.

Threshold Pharmaceuticals (NASDAQ:MTEM) last issued its quarterly earnings data on Monday, July 31st. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.99. The business had revenue of $3.00 million for the quarter. On average, analysts anticipate that Threshold Pharmaceuticals, Inc. will post ($0.74) EPS for the current fiscal year.

WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at

About Threshold Pharmaceuticals

Molecular Templates, Inc, formerly Threshold Pharmaceuticals, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Receive News & Stock Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.